// App-Quantinova.ai

260 : A longitudinal PET study to assess the state of microglia activation in a Phase 2 study of Laquinimod as a treatment for Huntington’s disease (LEGATO-HD)

Researchers

Presenter

  • A.A Roussakis

Principal Investigators

  • M. Gennaro

  • M.F Gordon

  • R. Reilmann

  • B. Borowsky

  • G. Rynkowski

  • J.M Savola

  • M.R Hayden

  • R. Gunn

  • S. Tabrizi

  • P. Piccini

Medical Centers

  • N/A

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Huntington's disease

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Cohort

Phase

  • II

Study Id's

  • NCT02215616

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved